Haleon

HLNNYSEUSD

THESIS ALERT

Email me when the HLN thesis changes

Evidence-based analysis, not personalized investment advice. Every alert email carries an unsubscribe link.

Follow on X
$9.10
+$0.04 (+0.44%)Today 1M −2.79%
After hours$9.100.00%

Updated Nov 11, 4:00 PM ET · Regular session · May be delayed

Source valuation snapshot. Not a live recalculation.
Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
Diluted earnings per share from the latest filed annual.
$9.06
Prior regular-session close from the quote source.
$8.98–$9.14
Regular-session low and high so far today.
21.4M
Regular-session shares traded · Nov 11, 4:00 PM ET.
Not yet confirmed
The company has not confirmed its next report date. Reported quarters are available in the chart’s Earnings view.
$8.38–$11.28
52-week trading low and high returned by the quote source.

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

The core investment thesis

Own HLN if Haleon turns a stable, large portfolio of branded over‑the‑counter consumer‑health products into cash through pricing power, scale and cost discipline; margins and free cash flow can rise even with low single‑digit top‑line growth, allowing.

HLN price history

Latest price$9.10Today+$0.04 (+0.44%)
HLN -3.88%S&P 500 -2.42%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

5 MATERIAL PROPOSITIONS
  • Haleon's gross-margin expansion is driven by pricing power and favorable product mix (brands over commoditized SKUs), so gross_profit should remain at or above recent levels absent a meaningful competitive or regulatory shock.StrengtheningMateriality: High

    gross_profit increased from 6,577,000,000 GBP (2022) to 7,080,000,000 GBP (2025), despite revenue being roughly flat. If gross margins stick, operating leverage will amplify profit and cash generation; if they revert, EPS and cash returns will be at risk.

    Watch: large retailers push private‑label expansion or demand markdowns that force branded price cuts.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    gross_profit increased from 6,577,000,000 GBP (2022) to 7,080,000,000 GBP (2025), despite revenue being roughly flat.

    Open source ↗
  • Management can convert flat or modest revenue growth into rising operating income and FCF through SG&A discipline and supply‑chain efficiency, so operating_income should continue to grow even without strong top‑line expansion.StrengtheningMateriality: High

    operating_income rose from 1,825,000,000 GBP (2022) to 2,412,000,000 GBP (2025) while revenue remained near £11bn. Sustained operating‑leverage conversion is the mechanism that turns stable revenue into rising EPS and buyback/dividend capacity.

    Watch: cost savings are largely one‑time (e.g., restructuring) and not repeatable, so running costs must be maintained for brands.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    operating_income rose from 1,825,000,000 GBP (2022) to 2,412,000,000 GBP (2025) while revenue remained near £11bn.

    Open source ↗
  • Haleon's portfolio delivers resilient, repeat purchase demand so revenue should remain broadly stable through cycles absent a brand‑level loss; demographic and category fundamentals support steady consumption rather than highly elastic demand.StrengtheningMateriality: Medium

    revenue has been roughly stable: 10,858,000,000 GBP (2022) → 11,302,000,000 GBP (2023) → 11,233,000,000 GBP (2024) → 11,030,000,000 GBP (2025). Revenue resilience limits downside and makes margin expansion more durable; if demand is elastic and falls, margins and cash quickly deteriorate.

    Watch: a national retailer or pharmacy chain delists or demotes a major brand in favor of private label, causing abrupt share loss.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    revenue has been roughly stable: 10,858,000,000 GBP (2022) → 11,302,000,000 GBP (2023) → 11,233,000,000 GBP (2024) → 11,030,000,000 GBP (2025).

    Open source ↗
  • Operating cash flow growth can fund dividends, buybacks or targeted M&A without materially increasing leverage, because FCF has improved alongside operating profit.HoldingMateriality: Medium

    operating_cash_flow increased from 2,063,000,000 GBP (2022) to 2,634,000,000 GBP (2025). If cash flow sustains, shareholders get returns or balance‑sheet strength; if cash weakens, expected returns or deleveraging won't materialize.

    Watch: large acquisitions, increased capex, or working‑capital swings consume available cash.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    operating_cash_flow increased from 2,063,000,000 GBP (2022) to 2,634,000,000 GBP (2025).

    Open source ↗
  • EPS progression (eps_diluted) is the stock's short‑term litmus: continued operational improvement should drive EPS higher even with flat revenue; failure to extend EPS gains signals the business model isn't delivering sustainable margin/cash improvements.StrengtheningMateriality: Medium

    eps_diluted rose from 0.115 GBP/shares (2022) to 0.157 (2024) and 0.185 (2025), showing recent earnings improvement. Investors price future EPS; sustained EPS growth validates the thesis and funds returns; EPS weakness would prompt re‑rating.

    Watch: incremental margin gains are offset by dilution, higher interest expense, or non‑operating charges.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    eps_diluted rose from 0.115 GBP/shares (2022) to 0.157 (2024) and 0.185 (2025), showing recent earnings improvement.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

Haleon's gross-margin expansion is driven by pricing power and favorable product mix (brands over commoditized SKUs), so gross_profit should remain at or above recent levels absent a meaningful competitive or regulatory shock. If gross margins stick, operating leverage will amplify profit and cash generation; if they revert, EPS and cash returns will be at risk.

Management can convert flat or modest revenue growth into rising operating income and FCF through SG&A discipline and supply‑chain efficiency, so operating_income should continue to grow even without strong top‑line expansion. Sustained operating‑leverage conversion is the mechanism that turns stable revenue into rising EPS and buyback/dividend capacity.

Haleon's portfolio delivers resilient, repeat purchase demand so revenue should remain broadly stable through cycles absent a brand‑level loss; demographic and category fundamentals support steady consumption rather than highly elastic demand. Revenue resilience limits downside and makes margin expansion more durable; if demand is elastic and falls, margins and cash quickly deteriorate.

Operating cash flow growth can fund dividends, buybacks or targeted M&A without materially increasing leverage, because FCF has improved alongside operating profit. If cash flow sustains, shareholders get returns or balance‑sheet strength; if cash weakens, expected returns or deleveraging won't materialize.

EPS progression (eps_diluted) is the stock's short‑term litmus: continued operational improvement should drive EPS higher even with flat revenue; failure to extend EPS gains signals the business model isn't delivering sustainable margin/cash improvements. Investors price future EPS; sustained EPS growth validates the thesis and funds returns; EPS weakness would prompt re‑rating.

All standing thesis claims
Original report summary

Haleon turns a stable, large portfolio of branded over‑the‑counter consumer‑health products into cash through pricing power, scale and cost discipline; margins and free cash flow can rise even with low single‑digit top‑line growth, allowing.

Evidence assessed Nov 6, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for Haleon

Where the evidence on Haleon stands: Holding on the latest evidence (Nov 6, 2026). Of its 5 thesis points, 4 strengthening and 1 holding.

Bull case: what the evidence supports

  • Haleon's gross-margin expansion is driven by pricing power and favorable product mix (brands over commoditized SKUs), so gross_profit should remain at or above recent levels absent a meaningful competitive or regulatory shock.

    sec.gov ↗

  • Management can convert flat or modest revenue growth into rising operating income and FCF through SG&A discipline and supply‑chain efficiency, so operating_income should continue to grow even without strong top‑line expansion.

    sec.gov ↗

  • Haleon's portfolio delivers resilient, repeat purchase demand so revenue should remain broadly stable through cycles absent a brand‑level loss; demographic and category fundamentals support steady consumption rather than highly elastic demand.

    sec.gov ↗

  • Operating cash flow growth can fund dividends, buybacks or targeted M&A without materially increasing leverage, because FCF has improved alongside operating profit.

    sec.gov ↗

  • EPS progression (eps_diluted) is the stock's short‑term litmus: continued operational improvement should drive EPS higher even with flat revenue; failure to extend EPS gains signals the business model isn't delivering sustainable margin/cash improvements.

    sec.gov ↗

Bear case: what would count against it

  • large retailers push private‑label expansion or demand markdowns that force branded price cuts.

    sec.gov ↗

  • cost savings are largely one‑time (e.g., restructuring) and not repeatable, so running costs must be maintained for brands.

    sec.gov ↗

  • a national retailer or pharmacy chain delists or demotes a major brand in favor of private label, causing abrupt share loss.

    sec.gov ↗

Thesis-Break Engine

What has broken in Haleon’s thesis

Each break OptimistFi flagged on Haleon, dated — with what has historically followed the same kind of break across the market, not a forecast for Haleon.

peers+18%-17%+1%12 mo agonow+6 mo
Daily price, then where similar breaks led across the market: the typical +1% path vs comparable companies over six months, inside the middle-half range (+18% to -17%). A base rate, not a forecast.
  • Sharp drawdowncondition set before this filing

    Across all companies, this kind of break has happened 15,428 times before. Those stocks beat comparable companies by a median of 1% over the next six months, and 33% of them trailed it by 10 points or more.

How the Thesis-Break Engine works →Historical outcomes are measured against comparable companies after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    DIRECTOR/PDMR SHAREHOLDING.

    Haleon filed an SEC report on 2026-11-02: DIRECTOR/PDMR SHAREHOLDING. It is a dated development that tests the current thesis.

  2. Mixed
    TOTAL VOTING RIGHTS AND CAPITAL.

    Haleon filed an SEC report on 2026-11-02: TOTAL VOTING RIGHTS AND CAPITAL. It is a dated development that tests the current thesis.

  3. Mixed
    TRANSACTIONS IN OWN SHARES.

    Haleon filed an SEC report on 2026-11-02: TRANSACTIONS IN OWN SHARES. It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • large retailers push private‑label expansion or demand markdowns that force branded price cuts.
  • cost savings are largely one‑time (e.g., restructuring) and not repeatable, so running costs must be maintained for brands.
  • a national retailer or pharmacy chain delists or demotes a major brand in favor of private label, causing abrupt share loss.
  • large acquisitions, increased capex, or working‑capital swings consume available cash.
  • incremental margin gains are offset by dilution, higher interest expense, or non‑operating charges.

HLN news

Loading headlines…

Financial statements

HLN income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

HLN: quick answers

What is HLN's short interest?
As of October 30, 2026, 14.6M HLN shares were sold short, down 21.3% from the count before. At the stock's average daily volume that is 1.0 day to cover. FINRA publishes the count twice a month. HLN short interest history
Have members of Congress traded HLN?
16 trades in HLN have been disclosed under the STOCK Act by members of Congress, the President or senior officials, none in reports made public in the last 90 days. Every disclosed HLN trade
Which well-known investors own HLN?
1 of the 37 well-known funds tracked here reported HLN shares in their latest 13F filing. By share of the fund's portfolio: Bridgewater Associates (Ray Dalio), 0.0%. Fund portfolios

HLN in well-known investors’ portfolios

1 of 37 funds reported HLN shares in their latest 13F filing. A 13F shows quarter-end positions and arrives up to 45 days later.

FundOf its portfolioValueChangeQuarter
Ray DalioBridgewater Associates0.02%$3.8MNewQ2 2026

Every fund’s portfolio

ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.